Page last updated: 2024-09-04

cyc 682 and Disease Models, Animal

cyc 682 has been researched along with Disease Models, Animal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Galmarini, CM	1

Other Studies

1 other study(ies) available for cyc 682 and Disease Models, Animal

Article	Year
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cytosine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Patents as Topic	2006

Article

Year

Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.

Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6

Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cytosine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Patents as Topic

2006